CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)

ARTIVION, INC.

2021-Q3 EPS reported $0.13 revenue$219,442,000

Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.
GAAP net income $10.6M ($0.26 EPS) vs net loss ($2.9M) year ago.
Non-GAAP net loss ($1.2M) ($0.03 EPS) vs prior non-GAAP net income $4.9M ($0.13).
2021 outlook: full-year revenue $296-299M; Q4 $76.5-79.5M, pro forma constant currency growth 9.5-13.7% vs Q4 2019.
Submitted PMAs to FDA for PerClot and PROACT Mitral; approvals expected in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.